Antipsychotic Selection in Parkinson’s Disease Psychosis With Comorbid Diabetes

Patient Background

Mr. James is a 76-year-old male with a medical history of Parkinson’s disease, type 2 diabetes mellitus, hypertension, and hyperlipidaemia. His Parkinson’s disease had progressed gradually over several years and was being managed with carbidopa/levodopa, with reasonable control of his motor symptoms.

His type 2 diabetes was also relatively stable, with a baseline HbA1c of 7.1%and body weight of 185 lb (84 kg).

Clinical Presentation

Over the preceding month, Mr. James’s family noticed the development of recurrent visual hallucinations. He described seeing unfamiliar people and animals inside his home despite recognizing at times that they were not actually present. The hallucinations initially caused little distress but subsequently became more frequent and disruptive.

After evaluation, the symptoms were considered consistent with Parkinson’s disease psychosis, and olanzapine was initiated to control the hallucinations.

Although the hallucinations improved, several clinically important adverse effects emerged over the following weeks. His family reported a marked increase in appetite, and his weight increased from 185 to 198 lb. Home fasting blood glucose measurements also became persistently elevated, with subsequent testing demonstrating a rising HbA1c.

Given the temporal relationship between olanzapine initiation and deterioration in metabolic control, the healthcare team suspected olanzapine-induced weight gain and hyperglycaemia.

Clinical Issue Identified

Medication review identified olanzapine as a suboptimal antipsychotic choice for this patient for two important reasons.

First, olanzapine has clinically relevant dopamine D₂ receptor antagonism. Dopaminergic deficiency within the nigrostriatal pathway is fundamental to Parkinson’s disease, and further D₂ receptor blockade can antagonize dopaminergic therapy and potentially worsen bradykinesia, rigidity, tremor, gait impairment, and overall motor function.

Second, olanzapine carries a substantial metabolic adverse-effect burden. It is strongly associated with increased appetite, weight gain, insulin resistance, hyperglycaemia, and dyslipidaemia. These effects are particularly problematic in a patient with established type 2 diabetes and cardiovascular risk factors.

The patient’s rapid weight gain and deterioration in glycaemic control therefore represented a clinically significant medication-related problem requiring reassessment of antipsychotic therapy.

Pharmacist Intervention and Clinical Management

Reassess potentially reversible causes of psychosis

Before escalating antipsychotic therapy, the healthcare team should evaluate for delirium, infection, metabolic disturbances, sleep disruption, dehydration, sensory impairment, and recently introduced medications that could contribute to hallucinations.

The patient’s complete Parkinson’s medication regimen should also be reviewed to determine whether potentially psychosis-provoking medications can be cautiously reduced without causing unacceptable deterioration in motor function.

Discontinue olanzapine

Given the worsening metabolic profile and potential for deterioration of Parkinsonian motor symptoms, olanzapine should be discontinued.

Blood glucose should be monitored following withdrawal because metabolic abnormalities may improve after removal of the offending medication.

Select a Parkinson’s-compatible treatment

If hallucinations remain sufficiently distressing or disruptive to require pharmacological treatment, an agent with minimal interference with nigrostriatal dopaminergic signalling should be selected.

Quetiapine may be initiated cautiously at a low dose and titrated according to clinical response and tolerability. Its relatively weak and transient D₂ receptor occupancy generally makes it less likely than olanzapine to exacerbate Parkinsonian motor symptoms.

However, quetiapine is not metabolically neutral and can still cause weight gain, hyperglycaemia, orthostatic hypotension, and sedation. Its efficacy for Parkinson’s disease psychosis is also less firmly established than that of some alternatives.

Where available and clinically appropriate, pimavanserin may be considered because it acts predominantly through 5-HT₂A inverse agonism without clinically meaningful dopamine D₂ receptor blockade, thereby minimizing the potential for worsening Parkinsonian motor function. Clozapine is another evidence-supported option but requires intensive hematological monitoring.

Monitor metabolic and neurological outcomes

Following the medication change, monitor:

• Hallucination frequency, severity, and associated distress
• Parkinsonian motor symptoms and mobility
• Body weight and appetite
• Fasting glucose and HbA1c
• Lipid profile
• Blood pressure, including orthostatic measurements
• Sedation, falls, and cognitive status

Educate the patient and family

The patient and caregivers should be advised to report worsening hallucinations, confusion, excessive sedation, falls, deterioration in mobility, increased appetite, or substantial changes in blood glucose.

Family observations are particularly valuable because changes in behaviour, cognition, and motor function may emerge gradually and may not always be recognized by the patient.

Clinical Rationale and Ramifications

This case demonstrates that antipsychotic selection in Parkinson’s disease requires consideration of both neurological and systemic adverse effects. The therapeutic objective is not simply to suppress hallucinations; psychosis must be controlled without substantially worsening the motor manifestations of Parkinson’s disease or aggravating existing comorbidities.

Olanzapine presents two major concerns in this setting. Its dopamine D₂ receptor antagonism can interfere with dopaminergic signalling and potentially worsen Parkinsonism, while its substantial metabolic burden can promote weight gain, insulin resistance, hyperglycaemia, and dyslipidaemia. In a patient with pre-existing type 2 diabetes, these metabolic consequences may accelerate deterioration in glycaemic control and increase long-term cardiovascular risk.

Although quetiapine is generally less likely than olanzapine to worsen Parkinsonian motor symptoms and has a comparatively lower metabolic burden, it should not be regarded as risk-free. Sedation, orthostatic hypotension, falls, and metabolic adverse effects remain important considerations in an older patient.

Importantly, antipsychotics used in older adults with dementia-related psychosis carry warnings regarding increased mortality, making careful assessment of indication, expected benefit, and treatment duration essential.

This case reinforces a fundamental principle of geriatric pharmacotherapy: the most effective medication for one symptom may still be inappropriate when its pharmacology conflicts with the patient’s underlying disease or comorbidities. Careful medication selection, conservative dosing, and ongoing reassessment are therefore essential when treating psychosis in Parkinson’s disease.